The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats
Open accessAbstract
Recent studies into the physiology of the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have added stimulation of β-cell growth, differentiation, and cell survival to well-documented, potent insulinotropic effects. Unfortunately, the therapeutic potential of these hormones is limited by their rapid enzymatic inactivation in vivo by dipeptidyl peptidase IV (DP IV). Inhibition of DP IV, so as to enhance circulating incretin levels, has proved effective in the treatment of type 2 diabetes both in humans and in animal models, stimulating improvements in glucose tolerance, insulin sensitivity, and β-cell function. We hypothesized that enhancement of the cytoprotective and β-cell regenerative effects of GIP and GLP-1 might extend the therapeutic potential of DP IV inhibitors to include type 1 diabetes. For testing this hypothesis, male Wistar rats, exposed to a single dose of streptozotocin (STZ; 50 mg/kg), were treated twice daily with the DP IV inhibitor P32/98 for 7 weeks. Relative to STZ-injected controls, P32/98-treated animals displayed increased weight gain (230%) and nutrient intake, decreased fed blood glucose (∼26 vs. ∼20 mmol/l, respectively), and a return of plasma insulin values toward normal (0.07 vs. 0.12 nmol/l, respectively). Marked improvements in oral glucose tolerance, suggesting enhanced insulin secretory capacity, were corroborated by pancreas perfusion and insulin content measurements that revealed two- to eightfold increases in both secretory function and insulin content after 7 weeks of treatment. Immunohistochemical analyses of pancreatic sections showed marked increases in the number of small islets (+35%) and total β-cells (+120%) and in the islet β-cell fraction (12% control vs. 24% treated) in the treated animals, suggesting that DP IV inhibitor treatment enhanced islet neogenesis, β-cell survival, and insulin biosynthesis. In vitro studies using a β-(INS-1) cell line showed a dose-dependent prevention of STZ-induced apoptotic cell-death by both GIP and GLP-1, supporting a role for the incretins in eliciting the in vivo results. These novel findings provide evidence to support the potential utility of DP IV inhibitors in the treatment of type 1 and possibly late-stage type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type 1 diabetes: new perspectives on disease pathogenesis and treatment
Atkinson, M. A., & Eisenbarth, G. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05415-0 · Cited by 1,491
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Self-citationKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Autonomic regulation of islet hormone secretion - Implications for health and disease
Ahrén, B. (2000) · Diabetologia · doi:10.1007/s001250051322 · Cited by 909
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Holz IV, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594
Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 1×
“A number of recent studies have highlighted the role of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in -cell function and development (2,3).”
BackgroundCD26, let it cut or cut it down
De Meester, I., Korom, S., Van Damme, J., & Scharpé, S. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01486-3 · Cited by 451
Perfetti, R. (2000) · Endocrinology · doi:10.1210/en.141.12.4600 · Cited by 442
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Buteau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413
Deacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
Tourrel, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 362
Creutzfeldt, W. O. C., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 330
Deacon, C. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3575 · Cited by 301
Pederson, R. A., White, H. A., Schlenzig, D., Pauly, R. P., McIntosh, C. H. S., & Demuth, H.-U. (1998) · Diabetes · doi:10.2337/diab.47.8.1253 · Cited by 267
Self-citationGuz, Y., Nasir, I., & Teitelman, G. (2001) · Endocrinology · doi:10.1210/endo.142.11.8501 · Cited by 254
Trümper, A., Trümper, K., Trusheim, H., Arnold, R., Göke, B., & Hörsch, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.9.0688 · Cited by 238
Pospisilik, J. A., Stafford, S. G., Demuth, H.-U., Brownsey, R., Parkhouse, W., Finegood, D. T., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.943 · Cited by 232
Self-citationDifferentiation of New Insulin-Producing Cells Is Induced by Injury in Adult Pancreatic Islets1
Fernandes, A., King, L. C., Guz, Y., Stein, R., Wright, C. V. E., & Teitelman, G. (1997) · Endocrinology · doi:10.1210/endo.138.4.5049 · Cited by 228
Hui, H., Wright, C., & Perfetti, R. (2001) · Diabetes · doi:10.2337/diabetes.50.4.785 · Cited by 223
Reimer, M., Holst, J., & Ahren, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460717 · Cited by 195
Jamen, F., Persson, K., Bertrand, G., Rodriguez-Henche, N., Puech, R., Bockaert, J., Ahrén, B., & Brabet, P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9387 · Cited by 190
Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM
Dupré, J., Behme, M., Hramiak, I., McFarlane, P. G., Williamson, M., Zabel, P., & Mcdonald, T. (1995) · Diabetes · doi:10.2337/diab.44.6.626 · Cited by 169
Pederson, R. A., Satkunarajah, M., McIntosh, C. H., Scrocchi, L. A., Flamez, D., Schuit, F., Drucker, D. J., & Wheeler, M. B. (1998) · Diabetes · doi:10.2337/diabetes.47.7.1046 · Cited by 167
Self-citationSudre, B., Broqua, P., White, R. B., Ashworth, D., Evans, D. M., Haigh, R., Junien, J.-L., & Aubert, M. L. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1461 · Cited by 165
Pauly, R. P., Rosche, F., Wermann, M., McIntosh, C. H. S., Pederson, R. A., & Demuth, H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23222 · Cited by 154
Self-citationPospisilik, J. A., Stafford, S. G., Demuth, H., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2677 · Cited by 146
Self-citationLambeir, A., Durinx, C., Proost, P., Damme, J. V., Scharpé, S., & Meester, I. D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02982-9 · Cited by 114
Pauly, R. P., Demuth, H., Rosche, F., Schmidt, J., White, H. A., Lynn, F. C., McIntosh, C. H. S., & Pederson, R. A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90090-2 · Cited by 102
Self-citationRecent Developments in Inhibiting Cysteine and Serine Proteases
Demuth, H. (1990) · Journal of enzyme inhibition · doi:10.3109/14756369009030375 · Cited by 92
Self-citationTrumper, A. (2001) · Molecular Endocrinology · doi:10.1210/me.15.9.1559 · Cited by 90
Metabolism of glucagon by dipeptidyl peptidase IV (CD26)
Pospisilik, J. A., Hinke, S. A., Pederson, R. A., Hoffmann, T., Rosche, F., Schlenzig, D., Glund, K., Heiser, U. F., McIntosh, C. H. S., & Demuth, H. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00170-1 · Cited by 70
Self-citationDachicourt, N., Serradas, P., Giroix, M.-H., Gangnerau, M.-N., & Portha, B. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.4.e725 · Cited by 53
Jia, X., Elliott, R. M., Kwok, Y. N., Pederson, R. A., & McIntosh, C. H. S. (1995) · Diabetes · doi:10.2337/diab.44.5.495 · Cited by 18
Self-citation
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Augeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
Metadata
- Authors
- Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2003-03-01
- Volume
- 52
- Issue
- 3
- Pages
- 741-750
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2154615287
- Cited by
- 332
- References
- 40
- FWCI
- 22.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.